Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · IEX Real-Time Price · USD
1.730
-0.070 (-3.89%)
May 3, 2024, 1:06 PM EDT - Market open
Fortress Biotech Stock Forecast
FBIO's stock price has decreased by -84.02% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Fortress Biotech stock have an average target of 33.33, with a low estimate of 10 and a high estimate of 75. The average target predicts an increase of 1,826.59% from the current stock price of 1.73.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 15, 2024.
Analyst Ratings
The average analyst rating for FBIO stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +478.03% | Mar 15, 2024 |
| Roth MKM | Roth MKM | Strong Buy Maintains $30 → $15 | Strong Buy | Maintains | $30 → $15 | +767.05% | Nov 29, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $75 | Buy | Reiterates | $75 | +4,235.26% | Aug 15, 2023 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $90 → $75 | Buy | Maintains | $90 → $75 | +4,235.26% | May 16, 2023 |
| Benchmark | Benchmark | Buy Reiterates $75 | Buy | Reiterates | $75 | +4,235.26% | Apr 6, 2023 |
Financial Forecast
Revenue This Year
75.76M
from 84.51M
Decreased by -10.35%
Revenue Next Year
128.36M
from 75.76M
Increased by 69.43%
EPS This Year
-4.78
from -8.47
EPS Next Year
-3.64
from -4.78
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 93.3M | 141.4M | 187.6M | 575.4M | 700.1M |
| Avg | 75.8M | 128.4M | 182.3M | 559.0M | 680.1M |
| Low | 58.5M | 114.7M | 175.1M | 537.0M | 653.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 10.4% | 86.6% | 46.2% | 215.7% | 25.3% |
| Avg | -10.4% | 69.4% | 42.0% | 206.7% | 21.7% |
| Low | -30.8% | 51.4% | 36.4% | 194.6% | 16.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -4.46 | -3.05 | -3.50 |
| Avg | -4.78 | -3.64 | -3.40 |
| Low | -5.02 | -4.16 | -3.26 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.